Solriamfetol’s Benefits for Daytime Sleepiness and Cognition Presented at NEI Congress
Summary: Axsome Therapeutics Inc presented data at NEI Congress 2024 on solriamfetol’s impact on excessive daytime sleepiness and cognitive function in patients with obstructive sleep apnea and narcolepsy. These findings, part of Axsome’s broader research portfolio, included insights from both real-world studies and clinical trials. Notable presentations focused on solriamfetol’s impact on wakefulness and cognitive…